Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 165

The DOI matches its Crossref record.

No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting

Open access
Jacob, Francis, Meier, Mara, Caduff, Rosmarie, Goldstein, Darlene, Pochechueva, Tatiana, Hacker, Neville, Fink, Daniel, Heinzelmann-Schwarz, Viola·2011·Gynecologic Oncology

Abstract

OBJECTIVE About 70% of epithelial ovarian cancer patients (EOC) are diagnosed at advanced stage with a five-year survival rate of only 30%. Whilst CA125 detects peritoneally-spread disease, it has limited sensitivity for early cancers, many of which are potentially curable. METHODS We compared the new commercially available tumor marker HE4 with CA125 individually, in combination, within the risk of malignancy index (RMI) and the newly defined risk of malignancy algorithm (ROMA). Our prospectively-collected cohort of 160 patients consisted of healthy controls, benign diseases, and borderline tumors/adenocarcinomas of ovarian, tubal, peritoneal and endometrial origin. HE4 and CA125 were measured in serum using standardized ELISA. RESULTS Both markers showed similar diagnostic performance in the detection of EOC at clinically defined thresholds (CA125 35U/ml; HE4 70pM) but HE4 was not elevated in endometriosis. Comparison of non-malignant diagnoses (n=71) versus early stage ovarian and tubal cancers (n=19) revealed that HE4 and ROMA displayed the best diagnostic performance (AUC 0.86/0.87, specificity 85.9%/87.3% and sensitivity 78.9%/78.9%, respectively). Whilst RMICA125 detects peritoneal cancer better than all other models (AUC 0.99, specificity 97.2%, sensitivity 80.0%), there is no other detection benefit from RMI compared to HE4 alone or included in ROMA. CONCLUSIONS The major advantage of HE4 lies in its specificity and improved detection of borderline tumors and early stage ovarian and tubal cancers. HE4 is superior to CA125 with or without RMI and ROMA indices. However, we see no benefit from combining both markers in clinical practice.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ygyno.2011.02.022

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 165

Metadata

Authors
Jacob, F., Meier, M., Caduff, R., Goldstein, D., Pochechueva, T., Hacker, N., Fink, D., & Heinzelmann-Schwarz, V.
Venue
Gynecologic Oncology
Publisher
Elsevier BV
Published
2011-06
Volume
121
Issue
3
Pages
487-491
ISSN
0090-8258 (ISSN-L)
OpenAlex
W2071541869
Cited by
165
References
0
FWCI
20.23
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting. https://app.cochat.ai/papers/10.1016/j.ygyno.2011.02.022
The paper
Jacob, F., Meier, M., Caduff, R., Goldstein, D., Pochechueva, T., Hacker, N., Fink, D., & Heinzelmann-Schwarz, V. (2011). No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting. Gynecologic Oncology. https://doi.org/10.1016/j.ygyno.2011.02.022

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.